![logo](/logos/FRLN.webp)
Freeline Therapeutics Holdings plc
NASDAQ:FRLN
6.48 (USD) • At close February 16, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Freeline Therapeutics Holdings plc |
Symbool | FRLN |
Munteenheid | USD |
Prijs | 6.49 |
Beurswaarde | 28,283,096 |
Dividendpercentage | 0% |
52-weken bereik | 2.11 - 8.745 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael J. Parini J.D. |
Website | https://www.freeline.life |
An error occurred while fetching data.
Over Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)